Information Remogliflozin etabonate (GSK189075) is an orally active, selective and low-affinity inhibitor ofsodium glucose cotransporter (SGLT2)with Ki of 1950 nM, 2140 nM, 43100 nM, 8570 nM for hSGLT2, rSGLT2, hSGLT1, rSGLT1, respectively. Remogliflozin etabonate exhibits antidiabetic efficacy in rodent models. Targets hSGLT2 (Cell-free assay); rSGLT2 (Cell-free assay); rSGLT1 (Cell-free assay); hSGLT1 (Cell-free assay) 1950 nM(Ki); 2140 nM(Ki); 8570 nM(Ki); 43100 nM(Ki)